


Substitute for form 1449A/PTO



# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application No.	09/966,515
Filing Date:	9/28/02
First Named Inventor	Kopreski
Group Art Unit	1655
Examiner Name	T. Lee
Attorney Docket No.	00-1312-C

Sheet

1

of

8

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
u	—	5,098,890		Gerwitz et al.	3/24/92	
	—	4,999,290		Lee	3/12/91	
	—	4,874,858		Magistro	10/17/89	
	—	4,699,877		Cline et al.	10/13/87	
	—	5,087,617		Smith	2/11/92	
	—	5,409,818		Davey et al.	4/25/95	
	—	4,683,195		Mullis et al.	7/28/87	
	—	5,470,724		Ahern	11/28/95	
	—	5,300,635		Macfarlane	4/5/94	
	—	5,217,889		Roninson et al.	6/8/93	
	—	5,124,246		Urdea et al.	6/23/92	
	—	5,274,087		Barnett et al.	12/28/93	
	—	5,155,018		Gillespie et al.	10/13/92	

RECEIVED

JUL 17 2002

TECH CENTER 1600/2900

## OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. 1	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
u	—	Abravaya et al., "Detection of point mutations with a modified ligase chain reaction (GAP-LCR)," <i>Nucleic Acids Research</i> 23:675-682 (1995)	—
	—	Alkema et al., "Characterization and Chromosomal Localization of the Human Prata-Oncogene BMI-1," <i>Human Mol Genet</i> 2:1597-1603 (1993)	—
	—	Aoki et al., "Liposome-mediated in vivo gene transfer on antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity," <i>Cancer Research</i> 55:3810-3816 (1995)	—

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

8

Complete if Known

Application No.

09/966,515

Filing Date:

9/28/02

First Named Inventor

Kopreski

Group Art Unit

1655

Examiner Name

Attorney Docket No.

00-13112-C

## OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
<i>u</i>	—	Barz et al., "Characterization of Cellular and Extracellular Plasma Membrane Vesicles from Non-metastasing Lymphoma (Eb) and Its Metastasing Variant (Esb)," <i>Biochin Biophys Acta</i> 814:77-84 (1985)
	—	Bauer et al., "Identification of H-2Kb Binding and Immunogenic Peptides from Human Papilloma Virus Tumour Antigens E6 and E7," <i>Scand J Immunol</i> 42:317-323 (1995)
	—	Blackburn et al., "Electrochemiluminescence detection for development of immunoassays and DNA probe assays for clinical diagnostics," <i>Olin Chem</i> 37/9:1534-1539 (1991)
	—	Bobo et al., "Diagnosis of chlamydia trachomatis cervical infection by detection of amplified DNA with an enzyme immunoassay," <i>J din Micra</i> 28:1968-1973 (1990)
	—	Bocchia et al., "Specific Binding of Leukemia Oncogene Fusion Peptides to HLA Class I Molecules," <i>Blood</i> 85:2680-2684 (1995)
	—	Boom et al., "Rapid and Simple Method for Purification of Nucleic Acids," <i>J Clin Micro</i> 28:495-503 (1990)
	—	Boom et al., "Rapid Purification of Hepatitis B Virus DNA from Seruc," <i>J Clin Micro</i> 29:180-181 (1991)
	—	Brossart et al., "Detection of residual tumor cells in patients with malignant melanoma responding to immunotherapy," <i>J Immunotherapy</i> 15:38-41 (1994)
	—	Buchman et al., "Selective RNA amplification: A novel method using d UMP-containing primers and uracil DNA glycosylase," <i>PCR Methods Applic</i> 3:28-31 (1993)
	—	Carr et al., "Circulating Membrane Vesicles in Leukemic Blood," <i>Cancer Research</i> 45:5944-5951 (1985)
	—	Cheung et al., "Rapid and Sensitive Method for Detection of Hepatitis C Virus RNA by Using Silica Particles," <i>J Clin Micro</i> 32:2593-2597 (1994)
	—	Chirgwin et al., "Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease," <i>Biochemistry</i> 18:5294-5299 (1979)
	—	Chomczynski and Mackey, "Modification of the TRI reagent (TM) procedure for isolation of RNA from polysaccharide- and proteoglycan-rich sources," <i>BioTechniques</i> 19:942-945 (1995)
↓	—	Chomczynski and Mackey, "Substitution of chloroform by bromo-chloropropane in the single-step method of RNA isolation," <i>Analytical Biochemistry</i> 225:163-164 (1995)

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application No.	09/966,515
Filing Date:	9/28/02
First Named Inventor	Kopreski
Group Art Unit	1655
Examiner Name	
Attorney Docket No.	00-1312-C

Sheet 3 of 8

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**


Examiner Initials*	Cite No. 1	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
<i>W</i>	—	Chomczynski et al., "Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction," <i>Analytical Biochemistry</i> 162:156-159 (1987)	—
	—	Chomczynski, "A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples," <i>Biotech</i> 15:532-537 (1993)	—
	—	Chu et al., "Thymidylate synthase binds to c-myc RNA in human colon cancer cells and in vitro," <i>Mol Cell Biol</i> 15:179-185 (1995)	—
	—	Cohen, "Biochemical Therapy: Antisense Compounds," In: <i>Biologic Teraphy of Cancer</i> (DeVita, Hellman, Rosenberg, eds) J.B. Lippincott, Ca., Philadelphia (1991) pp 763-775	—
	—	Colomer et al., "erb-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erb-2 oncogene amplification," <i>Br J Cancer</i> 70:819-825 (1994)	—
	—	Coutlee et al., "Immunodetection of DNA with biotinylated RNA probes: A study of reactivity of a monoclonal antibody to DNA-RNA hybrids," <i>Analytical Biochemistry</i> 181:96-105 (1989)	—
	—	Datta et al., "Sensitive Detection of Occult Breast Cancer by the Reverse-transcriptase Polymerase Chain Reaction," <i>Journal of Clinical Oncology</i> 12:475-482 (1994)	—
	—	Davidova and Shapot, "Liporibonucleoprotein Complex as an Integral Part of Animal Cell Plasma Membranes," <i>FEBS Lett</i> 6:349-351 (1970)	—
	—	DiCesare et al., "A high-sensitivity electrochemiluminescence-based detection system for automated PCR product quantitation," <i>BioTechniques</i> 15:152-157 (1993)	—
	—	Doi et al., "Detection of beta-human chorionic ganadotropin mRNA as a marker for cutaneous malignant melanoma," <i>Int J Cancer</i> 65:454-45- (1996)	—
	—	Dosaka et al., "A complex pattern of translational initiation and phosphorylation in L-Myc Proteins," <i>Oncogene</i> 6:371-378 (1991)	—
	—	Edmands et al., "Rapid RT-PCR Amplification from Limited Cell Numbers," <i>PCR Methods Applic</i> 3:317-319 (1994)	—
	—	Feng et al., "The RNA component of human telomerase," <i>Science</i> 269:1236-1241 (1995)	—
	—	Fournie et al., "Recovery of nanogram quantities of DNA from plasma and quantitative measurement using labeling by nick translation," <i>Analytical Biochemistry</i> 158:250-256 (1986)	—
	—	Gerhard et al., "Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction," <i>J Clin Oncol</i> 12:725-729 (1994)	—

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. The amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

**RECEIVED****JUL 17 2002****TECH CENTER 600/K200**



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

<b>Application No.</b>	<b>09/966,515</b>
<b>Filing Date:</b>	<b>9/28/02</b>
<b>First Named Inventor</b>	<b>Kopreski</b>
Group Art Unit	1655
Examiner Name	
Attorney Docket No.	00-1312-C

Sheet

4

of

8

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. 1	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
u	—	Gerhard et al., "Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction," <i>J Clin Oncol</i> 12:725-729 (1994)	—
	—	Ghossein et al., "Detection of Circulating Tumor Cells in Patients with Localized and Metastatic Prostatic Carcinoma: Clinical Implications," <i>Journal of Clinical Oncology</i> 13:1195-1200 (1995)	—
	—	Higashiyama et al., "Reduced Motility Related Protein-1 (MRP-1/CD9) Gene Expression as a Factor of Poor Prognosis in Non-small Cell Lung Cancer," <i>Cancer Research</i> 55:6040-6044 (1995)	—
	—	Hoon et al., "Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay," <i>J Clin Oncol</i> 13:2109-2116 (1995)	—
	—	Hoover et al., "Immunotherapy by Active Specific Immunization: Clinical Applications," <i>In: Biologic- Therapy of Cancer (DeVita, Hellman, Rosenberg, eds)</i> J.B. Lippincott, Co., Philadelphia (1991) pp 670-682	—
	—	Imai et al., "Detection of HIV-1 RNA in Heparinized Plasma of HIV-1 Seropositive Individuals," <i>J Virol Methods</i> 36:181-184 (1992)	—
	—	Jrdea et al., "Direct and quantitative detection of HIV-I RNA in human plasma with a branched DNA signal amplification assay," <i>AIDS</i> 7(suppl 2):S11-514 (1993)	—
	—	Juckett and Rosenberg, "Actions of Cis-diamminedichloroplatinum on Cell Surface Nucleic Acids in Cancer Cells as Determined by Cell Electrophoresis Techniques," <i>Cancer Research</i> 42:3565-3573 (1982)	—
	—	Kahn et al., "Rapid and sensitive nonradioactive detection of mutant K-ras genes via enriched PCR amplification," <i>Oncogene</i> 6:1079-1083 (1991)	—
	—	Kamm and Smith, "Nucleic acid concentrations in normal human plasma," <i>Clinical Chemistry</i> 18:519- 522 (1972)	—
	—		—

**RECEIVED****JUL 17 2002****TECH CENTER 1600/2900**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.  
Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

Substitute for form 1449A/PTO



# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application No.	09/966,515
Filing Date:	9/28/02
First Named Inventor	Kopreski
Group Art Unit	1655
Examiner Name	
Attorney Docket No.	00-1312-C

Sheet	5	of	8
-------	---	----	---

## OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. 1	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
W	—	Karet et al., "Quantification of mRNA in human tissue using fluorescent nested reverse-transcriptase polymerase chain reaction," <i>Analytical Biochemistry</i> 220:384-390 (1994)	—
	—	Katz et al., "Enhanced Reverse Transcriptase-Polymerase Chain Reaction for Prostate Specific Antigen as a Indicator of True Pathologic Stage in Patients with Prostate Cancer," <i>Cancer</i> 75:1642-1648 (1995)	—
	—	Kievits et al., "NASBA(TM) isothermal enzymatic in vitro nucleic acid amplification optimized for the diagnosis of HIV-1 infection," <i>J Virological Methods</i> 35:273-286 (1991)	—
	—	Kim et al., "Specific association of human telomerase activity with immortal cells and cancer," <i>Science</i> 266:2011-2015 (1994)	—
	—	Komeda et al., "Sensitive detection of circulating hepatocellular carcinoma cells in peripheral venous load," <i>Cancer</i> 75:2214-2219 (1995)	—
	—	Landgraf et al., "Direct analysis of polymerase chain reaction products using enzyme-linked immunosorbent assay techniques," <i>Analytical Biochemistry</i> 198:86-91 (1991)	—
	—	Landgraf et al., "Quantitative analysis of polymerase chain reaction (PCR) products using primers labeled with biotin and a fluorescent dye," <i>Analytical Biochemistry</i> 193:231-235 (1991)	—
	—	Larson et al., "Radioisotope Conjugates," In: <i>Biologic Therapy of Cancer</i> (DeVita, Hellman, Rosenberg, eds) J.B. Lippincott, Co., Philadelphia (1991) pp 496-511	—
	—	Leon et al., "A Comparison of DNA and DNA-binding Protein Levels in Malignant Disease," <i>Europ J Cancer</i> 17:533-538 (1981)	—
	—	Maruyama et al., "Detection of AMLi/ETO fusion transcript as a tool for diagnosing t(8;21) positive acute myelogenous leukemia," <i>Leukemia</i> 8:40-45 (1994)	—
	—	Masella et al., "Characterization of Vesicles, Containing an Acylated Oligopeptide, Released by Human Colon Adenocarcinoma Cells," <i>FEBS Lett</i> 246:25-29 (1989)	—
✓	—	McCabe et al., "Minimal Determinant Expressed by a Recombinant Vaccinia Virus Elicits Therapeutic Antitumor Cytolytic T Lymphocyte Responses," <i>Cancer Research</i> 55:1741-1747 (1995)	—

RECEIVED

JUL 17 2002

TECH CENTER 1600/2900

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

6

of

8

## Complete if Known

Application No.

09/966,515

Filing Date:

9/28/02

First Named Inventor

Kopreski

Group Art Unit

1655

Examiner Name

Attorney Docket No.

00-1312-C

## OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. 1	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
<i>u</i>	—	Miller et al., "Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-alpha fusion mRNA," <i>Blood</i> 82:1689-1694 (1993)	—
	—	Moore et al., "Design of PCR primers that detect only mRNA in the presence of DNA," <i>Nucleic Acids Research</i> 18:1921 (1991)	—
	—	Mori, et al., "Detection of Cancer Micrometastases in Lymph Nodes by Reverse Transcriptase-Polymerase Chain Reaction," <i>Cancer Research</i> 55:3417-3420 (1995)	—
	—	Mountford et al., "Proteolipid Identified by Magnetic Resonance Spectroscopy in Plasma of a Patient with Borderline Ovarian Tumor," <i>Lancet</i> i:829-834 (1987)	—
	—	Nguyen, "Southern blot analysis of polymerase chain reaction products on acrylamide gels," <i>BioTechniques</i> 7:238-240 (1989)	—
	—	Ozcelik et al., "Low Levels of Expression of an Inhibitor of Cyclin-dependent Kinases (CIP1/WAF1) in Primary Breast Carcinomas with p53 Mutations," <i>Clinical Cancer Research</i> 1:907-912 (1995)	—
	—	Patard et al., "Expression of MAGE genes in transitional-cell carcinomas of the urinary bladder," <i>mt J Cancer</i> 64:60-64 (1995)	—
	—	Penno et al., "Expression of CD44 in human lung tumors," <i>Cancer Research</i> 54:1381-1387 (1994)	—
	—	Peoples et al., "Breast and Ovarian Cancer-Specific Cytotoxic T Lymphocytes Recognize the same HER-2/Neu Derived Peptide," <i>Proc Natl Acad Sci USA</i> 92:432-436 (1995)	—
	—	Pfleiderer et al., "Detection of tumor cells in peripheral blood and bone marrow from ewing tumor patients by RT-PCR," <i>Int J Cancer (Pred. Oncol)</i> 64:135-139 (1995)	—
	—	Polushin et al., "Antisense Pro-Drugs: 5'-ester oligodeoxynucleotides," <i>Nucleic Acids Research</i> 22:5492-5496 (1994)	—
	—	Rashtchian, "Amplification of RNA," <i>PCR Methods Applic</i> 4:S83-S91 (1994)	—
	—	Reddi and Holland, "Elevated Serum Ribonuclease in Patients with Pancreatic Cancer," <i>Proc Nat Acad Sci USA</i> 73:2308-2310 (1976)	—
	—		—

RECEIVED

JUL 17 2002

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English translation is attached.

TECH CENTER 1600/2900

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

7

of

8

Complete if Known

Application No.

09/966,515

Filing Date:

9/28/02

First Named Inventor

Kopreski

Group Art Unit

1655

Examiner Name

Attorney Docket No.

00-1312-C

## OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. 1	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
<i>W</i>	—	Rieber and Bacalao, "An 'external' RNA removable from mammalian cells by mild proteolysis," <i>Proc Natl Acad Sci USA</i> 71:4960-4964 (1974)	—
	—	Roggenbuck et al., "Human Papillomavirus Type 18 E6 and E6, and E7 Protein Synthesis in Cell Free Translation Systems and Comparison of E6 and E7 in Vitro Translation Products to Proteins Immunoprecipitated from Human Epithelial Cells," <i>J Viral</i> 65:5068-72 (1991)	—
	—	Rosenberg-Nicolson et al., "Nucleoprotein Complexes Released from Lymphoma Nuclei that Contain the abl Oncogene and RNA and DNA Polymerase and RNA Primase Activities," <i>J Cell Biochem</i> 50:43-52 (1992)	—
	—	Rosi et al., "RNA-Lipid Complexes Released from the Plasma Membrane of Human Colon Carcinoma Cells," <i>Cancer Lett</i> 39:153-160 (1988)	—
	—	Saiki et al., "Genetic analysis of amplified DNA with immobilized sequence-specific oligonucleotide probes," <i>Science</i> 233:1076-1078 (1989)	—
	—	Sakakura et al., "Inhibition of gastric cancer cell proliferation by antisense oligonucleotides targeting the messenger RNA encoding proliferating cell nuclear antigen," <i>Br J Cancer</i> 70:1060-1066 (1994)	—
	—	Schlom, "Antibodies in cancer therapy: basic principles of monoclinal antibodies," <i>In: Biologic Therapy of Cancer</i> , (DeVita, Hellman, Hellman, Rosenberg, eds) J.B. Lippincott, Co., Philadelphia (1991) pp 464-481	—
	—	Shea et al., "Identification of the Human Prostate Carcinoma Onogene PTI-1 by Rapid Expression Cloning and Differential RNA Display," <i>Proc Natl Acad Sci USA</i> 92:6778-6782 (1995)	—
	—	Skorski et al., "Suppression of philadelphial leukemia cell growth in mice by BORABL antisense oligodeoxynucleotide," <i>Proc Natl Acad Sci USA</i> 91:4504-4508 (1994)	—
	—	Smith et al., "Detection of Melanoma Cells in Peripheral Blood by Means of Reverse Transcriptase and Polymerase Chain Reaction," <i>Lancet</i> 338:1227-1229 (1991)	—
↓	—	Sooknanan et al., "Detection and direct sequence identification of BCR-ABL mRNA in Ph+ chronic myeloid leukemia," <i>Experimental Hematology</i> 21:1718-1724 (1993)	—

RECEIVED

JUL 17 2002

TECH CENTER 1600/2900

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to compete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

8

of

8

Complete if Known

Application No.

09/966,515

Filing Date:

9/28/02

First Named Inventor

Kopreski

Group Art Unit

1655

Examiner Name

Attorney Docket No.

00-1312-C

## OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. 1	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
u	—	Stock et al., "Value of molecular monitoring during the treatment of chronic myeloid leukemia: A cancer and leukemia group B study," <i>J Clin Oncology</i> 15:26-36 (1997)	—
	—	Stroun et al., "Neoplastic characteristics of the DNA found in the plasma of cancer patients," <i>Oncology</i> 46:318-322 (1989)	—
	—	Taylor and Blak, "Shedding of Plasma Membrane Fragments. Neoplastic and Developmental Importance," <i>In: The Cell Surface in Development and Cancer, Develop Biol</i> 3:33-57 Editor: M.S. Steinberg. Plenum Press, New York, London (1985)	—
	—	Urdea et al., "Branched DNA amplification multimers for the sensitive, direct detection of human hepatitis viruses," <i>Nucleic Acids Research Symposium Series</i> 24:197-200 (1991)	—
	—	Vandamme et al., "Detection of HIV-1 RNA in plasma and serum samples using the NASBA amplification system compared to RNA-PCR," <i>J Virological Methods</i> 52:121-132 (1995)	—
	—	Vitetta et al., "Immunotoxins," <i>In: Biologic Therapy of Cancer (DeVita, Hellman, Rosenberg, eds)</i> J.B. Lippincott, Co., Philadelphia (1991) pp 482-495	—
	—	Wang et al., "Quantitation of mRNA by the polymerase chain reaction," <i>Proc Natl Acad Sci USA</i> 86:9717-9721 (1989)	—
	—	Wieczorek et al., "Diagnostic and Prognostic Value of RNA-Proteolipid in Sera of Patients with Malignant Disorders Following Therapy; First Clinical Evaluation of a Novel Tumor Marker," <i>Cancer Research</i> 47:6407-6412 (1987)	—
	—	Wieczorek et al., "Gensondentest Fur RNA-Proteolipid in Serumproben Bei Neoplasie," <i>Schweiz med Wschr</i> 119:1342-1343 (1989)	—
	—	Wieczorek et al., "Isolation and Characterization of an RNA-Proteolipid Complex Associated with the Malignant State in Humans," <i>Proc Natl Acad Sci USA</i> 82:3455-3459 (1985)	—
	—	Wiedmann et al., "Ligase chain reaction (LCR)—overview and applications," <i>POR Methods Applic</i> 3:551-564 (1994)	—
	—	Yanuck et al., "A Mutant P53 Tumor Suppressor Protein is a Target for Peptide-Induced ODB' Cytotoxic T-Cells," <i>Cancer Research</i> 52:3257-3261 (1993)	—

RECEIVED

JUL 17 2002

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231